Effective Combination Strategy to Overcome Resistance Mechanism in RAS-Driven Cancers
- Introduction of Hanmi Pharmaceuticals and Oncology Pipelines
- Belvarafenib, a selective type II RAF dimer inhibitor with anti-tumor activities in NRAS mutant melanoma from pre-clinical and clinical
- HM101207, a highly selective SOS1-panKRAS modulator and promising combination to treat KRAS-MAPK driven cancers